Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Inclisiran (Leqvio): Canagliflozin has the stronger overall evidence (4.5 vs 4.1/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Canagliflozin wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Canagliflozin and Inclisiran (Leqvio) have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (canagliflozin)
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
Any time of day
Prefilled subcutaneous injection (inclisiran 284 mg)
Weeks
Unknown in humans
Months to years
Weeks to months
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
Canagliflozin has a higher evidence score (4.5/10 vs 4.1/10) and wins in 2 of 3 categories.
Both Canagliflozin and Inclisiran (Leqvio) score equally (70) for support heart health.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.